Top

Published in:

01-12-2021 | Gout | Research article

SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout

Authors: Jasvinder A. Singh, Amy Joseph, Joshua Baker, Joshua S. Richman, Terrence Shaneyfelt, Kenneth G. Saag, Seth Eisen

Published in: BMC Medicine | Issue 1/2021

Abstract

Background

Urate-lowering therapy (ULT) adherence is low in gout, and few, if any, effective, low-cost, interventions are available. Our objective was to assess if a culturally appropriate gout-storytelling intervention is superior to an attention control for improving gout outcomes in African-Americans (AAs).

Methods

In a 1-year, multicenter, randomized controlled trial, AA veterans with gout were randomized to gout-storytelling intervention vs. a stress reduction video (attention control group; 1:1 ratio). The primary outcome was ULT adherence measured with MEMSCap™, an electronic monitoring system that objectively measured ULT medication adherence.

Results

The 306 male AA veterans with gout who met the eligibility criteria were randomized to the gout-storytelling intervention (n = 152) or stress reduction video (n = 154); 261/306 (85%) completed the 1-year study. The mean age was 64 years, body mass index was 33 kg/m², and gout disease duration was 3 years. ULT adherence was similar in the intervention vs. control groups: 3 months, 73% versus 70%; 6 months, 69% versus 69%; 9 months, 66% versus 67%; and 12 months, 61% versus 64% (p > 0.05 each). Secondary outcomes (gout flares, serum urate and gout-specific health-related quality of life [HRQOL]) in the intervention versus control groups were similar at all time points except intervention group outcomes were better for the following: (1) number of gout flares at 9 months were fewer, 0.7 versus 1.3 in the previous month (p = 0.03); (2) lower/better scores on two gout specific HRQOL subscales: gout medication side effects at 3 months, 32.8 vs. 39.6 (p = 0.02); and unmet gout treatment need at 3 months, 30.9 vs. 38.2 (p = 0.003), and 6 months, 29.5 vs. 34.5 (p = 0.03), respectively.

Conclusions

A culturally appropriate gout-storytelling intervention was not superior to attention control for improving gout outcomes in AAs with gout.

Trial registration

Registered at ClinicalTrials.gov NCT02741700

Available only for authorised users

Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136–41. https://doi.org/10.1002/art.30520.CrossRefPubMed

Hochberg MC, Thomas J, Thomas DJ, Mead L, Levine DM, Klag MJ. Racial differences in the incidence of gout. The role of hypertension. Arthritis Rheum. 1995;38(5):628–32. https://doi.org/10.1002/art.1780380508.CrossRefPubMed

Krishnan E, Lienesch D, Kwoh CK. Gout in ambulatory care settings in the United States. J Rheumatol. 2008;35(3):498–501.PubMed

FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020;72(6):879–95. https://doi.org/10.1002/art.41247.CrossRefPubMed

Solomon DH, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008;67(5):609–13. https://doi.org/10.1136/ard.2007.076182.CrossRefPubMed

Coley K, Saul M, Pater K. Relationship between race, uric acid levels, urate-lowering therapy and resource use in patients with gout. Arthritis Rheum. 2012;64(10 Suppl):S772.

Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81(7):925–34. https://doi.org/10.4065/81.7.925.CrossRefPubMed

Singh JA, Hodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis. 2009;68(8):1265–70. https://doi.org/10.1136/ard.2008.092619.CrossRefPubMed

Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28(4):437–43. https://doi.org/10.1592/phco.28.4.437.CrossRefPubMedPubMedCentral

10.

Harrold LR, Mazor KM, Velten S, Ockene IS, Yood RA. Patients and providers view gout differently: a qualitative study. Chronic Illn. 2010;6(4):263–71. https://doi.org/10.1177/1742395310378761.CrossRefPubMedPubMedCentral

11.

Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis. 2012;71(9):1490–5. https://doi.org/10.1136/annrheumdis-2011-200801.CrossRefPubMed

12.

Dalbeth N, Petrie KJ, House M, Chong J, Leung W, Chegudi R, et al. Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Arthritis Care Res (Hoboken). 2011;63(11):1605–12. https://doi.org/10.1002/acr.20570.CrossRef

13.

Singh JA, Herbey I, Bharat A, Dinnella JE, Pullman-Mooar S, Eisen S, et al. Gout self-management in African American veterans: a qualitative exploration of challenges and solutions from patients’ perspectives. Arthritis Care Res (Hoboken). 2017;69(11):1724–32. https://doi.org/10.1002/acr.23202.CrossRef

14.

Singh JA. SToRytelliing to Improve Disease outcomes in Gout (STRIDE-GO) in African American veterans with gout: a trial study protocol (submitted). Trials. 2021.

15.

Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895–900. https://doi.org/10.1002/art.1780200320.CrossRefPubMed

16.

Neogi T, Chen C, Niu J, Chaisson C, Hunter DJ, Zhang Y. Alcohol quantity and type on risk of recurrent gout attacks: an internet-based case-crossover study. Am J Med. 2014;127(4):311–8. https://doi.org/10.1016/j.amjmed.2013.12.019.CrossRefPubMedPubMedCentral

17.

Voils CI, Maciejewski ML, Hoyle RH, Reeve BB, Gallagher P, Bryson CL, et al. Initial validation of a self-report measure of the extent of and reasons for medication nonadherence. Med Care. 2012;50(12):1013–9. https://doi.org/10.1097/MLR.0b013e318269e121.CrossRefPubMedPubMedCentral

18.

Greenlaw SM, Yentzer BA, O'Neill JL, Balkrishnan R, Feldman SR. Assessing adherence to dermatology treatments: a review of self-report and electronic measures. Skin Res Technol. 2010;16(2):253–8. https://doi.org/10.1111/j.1600-0846.2010.00431.x.CrossRefPubMed

19.

Nakonezny PA, Byerly MJ, Rush AJ. Electronic monitoring of antipsychotic medication adherence in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of its reliability and predictive validity. Psychiatry Res. 2008;157(1-3):259–63. https://doi.org/10.1016/j.psychres.2007.05.001.CrossRefPubMed

20.

Hirsch JD, Lee SJ, Terkeltaub R, Khanna D, Singh J, Sarkin A, et al. Evaluation of an instrument assessing influence of Gout on health-related quality of life. J Rheumatol. 2008;35(12):2406–14. https://doi.org/10.3899/jrheum.080506.CrossRefPubMed

21.

Khanna D, Sarkin AJ, Khanna PP, Shieh MM, Kavanaugh AF, Terkeltaub RA, et al. Minimally important differences of the gout impact scale in a randomized controlled trial. Rheumatology (Oxford). 2011;50(7):1331–6. https://doi.org/10.1093/rheumatology/ker023.CrossRef

22.

Ruiz MA, Pardo A, Rejas J, Soto J, Villasante F, Aranguren JL. Development and validation of the "Treatment Satisfaction with Medicines Questionnaire" (SATMED-Q). Value Health. 2008;11(5):913–26. https://doi.org/10.1111/j.1524-4733.2008.00323.x.CrossRefPubMed

23.

Stanbio Laboratory. An EKF Diagnostics Company. Uric Acid LiquiColor® Test (Enzymatic). https://www.ekfusa.com/chemistry_range/all-reagents/. [online]

24.

Shoemaker SJ, Wolf MS, Brach C. Patient Education Materials Assessment Tool for Audiovisual Materials (PEMAT-A/V). (Prepared by Abt Associates, under Contract No. HHSA290200900012I, TO 4). Publication No. 14-0002-EF. In. Agency for Healthcare Research and Quality: Rockville, MD; 2013.

25.

Mitcheli AJ, Selmes T. Why don’t patients take their medication? Reasons and solutions in psychiatry. Adv Psyhiatric Treatment. 2007;13(5):336–46. https://doi.org/10.1192/apt.bp.106.003194.CrossRef

26.

Hopfer S. Effects of a narrative HPV vaccination intervention aimed at reaching college women: a randomized controlled trial. Prev Sci. 2012;13(2):173–82. https://doi.org/10.1007/s11121-011-0254-1.CrossRefPubMed

27.

Singh JA. Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study. Arthritis Res Ther. 2014;16(2):R82. https://doi.org/10.1186/ar4524.CrossRefPubMedPubMedCentral

28.

Rosenstock IM. Why people use health services. Milbank Mem Fund Q. 1966;44(3):94–127. https://doi.org/10.2307/3348967.CrossRef

29.

Slater M, Rouner D. Entertainment-education and elaboration likelihood: understanding the processing of narrative persuasion. Commun Theory. 2002;12(1):173–91. https://doi.org/10.1111/j.1468-2885.2002.tb00265.x.CrossRef

30.

Agha Z, Lofgren RP, Vanruiswyk JV, Layde PM. Are patients at veterans affairs medical centers sicker? Arch Intern Med. 2000;160(21):3252–7. https://doi.org/10.1001/archinte.160.21.3252.CrossRefPubMed

Title: SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout
Authors: Jasvinder A. Singh
Amy Joseph
Joshua Baker
Joshua S. Richman
Terrence Shaneyfelt
Kenneth G. Saag
Seth Eisen
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Gout
Published in: BMC Medicine / Issue 1/2021
Electronic ISSN: 1741-7015
DOI: https://doi.org/10.1186/s12916-021-02135-w

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout

Abstract

Background

Methods

Results

Conclusions

Trial registration

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2021

Ketone bodies: from enemy to friend and guardian angel

Comparison of submucosal and subserosal approaches toward optimized indocyanine green tracer-guided laparoscopic lymphadenectomy for patients with gastric cancer (FUGES-019): a randomized controlled trial

Clinicopathologic analysis of microscopic tumor extension in glioma for external beam radiotherapy planning

Targeting body composition in an older population: do changes in movement behaviours matter? Longitudinal analyses in the PREDIMED-Plus trial

A heart failure phenotype stratified model for predicting 1-year mortality in patients admitted with acute heart failure: results from an individual participant data meta-analysis of four prospective European cohorts

Temporal trends in cause-specific mortality among individuals with newly diagnosed atrial fibrillation in the Framingham Heart Study